Search clinical trials for: Aggressive behavior

Total 71223 results

Canadian Cancer Trials Group
AbbVie; Roche Pharma AG; Incyte Corporation

Recruiting

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Lymphoma, B-Cell

Canada
Medical University of South Carolina
National Institute on Minority Health and Health Disparities (NIMHD)

Recruiting

Enhancing School-Based Violence Prevention

Aggressive Childhood Behavior

United States
Immunis.AI

Recruiting

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

Prostate Cancer Aggressiveness

United States
University Hospital, Limoges

Recruiting

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas (ExoReBLy)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)

France
University of Alberta
Alberta Cancer Foundation; Canadian Cancer Trials Group

Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)

Relapsed Non Hodgkin Lymphoma | Relapsed Pediatric ALL | Relapsed Adult ALL

Canada
Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
Meirav Kedmi MD

Recruiting

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy (NivoM)

Lymphoma, B-Cell

Israel
yu gengsheng

Recruiting

Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Stage IV | Thoracic Radiotherapy

China
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
MingSight Pharmaceuticals, Inc

Recruiting

A Study Of The Selective PKC-β Inhibitor MS- 553

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Aggressive Lymphoma

United States
Ohio State University

Recruiting

Aggressive Driving and Road Rage: A Driving Simulation Experiment.

Aggression

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013)

Mature B-cell Non-Hodgkin Lymphoma

Austria, Czechia, Denmark, Finland, Germany, Norway, Sweden, Switzerland
University of Illinois at Chicago

Recruiting

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sickle Cell Disease

United States
M.D. Anderson Cancer Center

Recruiting

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Multiple Endocrine Neoplasia

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (CLIO-1)

Relapsed/Refractory Aggressive B-Cell Lymphoma

United States, Germany, Spain
Canadian Cancer Trials Group
Roche Pharma AG; Janssen, LP; Karyopharm Therapeutics Inc

Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Lymphoma

Canada
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid Neoplasm | Neuroendocrine Neoplasm | Myeloproliferative Neoplasm | Desmoid Fibromatosis | Lymphoproliferative Disorder | Carcinoma In Situ | Central Nervous System Neoplasm | Ganglioneuroma | Congenital Mesoblastic Nephroma | Childhood Immature Teratoma | Childhood Langerhans Cell Histiocytosis and other conditions

United States, Puerto Rico, Canada, Australia, New Zealand, Saudi Arabia
Fondazione Italiana Linfomi ONLUS

Recruiting

Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy

Non Hodgkin Lymphoma

Italy
michal roll

Recruiting

Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors

Surgical Resection | The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an | Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After

Israel
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Diffuse Large B-Cell Lymphoma | Chronic Lymphocytic Leukemia | Anaplastic Large Cell Lymphoma | Small Lymphocytic Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin Lymphoma | Enteropathy-Associated... and other conditions

United States
University of Illinois at Chicago

Recruiting

Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Sickle Cell Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) | Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

United States
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
National Cancer Institute (NCI)

Completed

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Hormone Receptor-Positive Breast | Gynecologic | Desmoid | Hormone Receptor-Positive Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Completed

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Unresectable Solid Neoplasm | Recurrent Solid Neoplasm | Refractory Mantle Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Advanced Solid Neoplasm | T-Cell Non-Hodgkin Lymphoma

United States
SpringWorks Therapeutics, Inc.

Active, not recruiting

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi)

Desmoid Tumor | Aggressive Fibromatosis

United States, Belgium, Germany, Canada, Italy, Netherlands, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
Centre Oscar Lambret
Institut Curie; Ligue contre le cancer, France; Hôpital de la Timone

Active, not recruiting

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) (ALTITUDES)

Aggressive Fibromatosis

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Prostate Carcinoma | Prostate Cancer Aggressiveness

United States
M.D. Anderson Cancer Center

Active, not recruiting

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Breast Cancer

United States
Hyo Song Kim

Completed

A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Desmoid Tumor

Korea, Republic of
AstraZeneca

Active, not recruiting

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Extensive-stage Small Cell Lung Cancer

Canada, Germany, Italy, Czechia, Turkey, Bulgaria
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed... and other conditions

United States
Universität des Saarlandes
Spectrum Pharmaceuticals, Inc; German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (OPTIMAL>60)

CD20+ Aggressive B-Cell Lymphoma

Germany
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

An MRI Ancillary Study of a Malaria Fever Investigation (MRIA)

Brain Injuries | Chronic Kidney Diseases | Malaria | Behavior Problem | MRI Imaging | Neurocognitive Deficits

Zambia, Malawi
Novartis Pharmaceuticals

Available

Managed Access Programs for PKC412, Midostaurin

Acute Myeloid Leukemia | Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm | FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
Cedars-Sinai Medical Center

Completed

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial (CARMA)

Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
Fox Chase Cancer Center

Suspended

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

Lymphoma

United States
SpringWorks Therapeutics, Inc.

Available

Individual Patient Compassionate Use of Nirogacestat

Desmoid Tumor | NOTCH Gene Mutation Positive Tumors
Ayala Pharmaceuticals, Inc,

Active, not recruiting

A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)

Desmoid Tumor | Desmoid

United States, Spain, United Kingdom, Australia, Korea, Republic of, Israel, Belgium, Germany, Netherlands, Italy, Poland

Search clinical trials for: Aggressive behavior

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations